Greenbrook

What Greenbrook does

Greenbrook is a privately held, specialty outpatient mental health treatment provider founded in 2011, operating approximately 95 treatment centers across the United States through its legal entity Greenbrook TMS NeuroHealth Centers. The company delivers two FDA-cleared/approved advanced therapies for treatment-resistant depression (TRD) and obsessive-compulsive disorder (OCD): NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy, which uses focused magnetic pulses to stimulate dormant synapses, and SPRAVATO (esketamine) nasal spray, an NMDA-receptor antagonist delivered under the SPRAVATO REMS restricted program. The company's stated clinical focus is adult and adolescent (ages 15-21) major depressive disorder and OCD in patients who have not achieved adequate response from traditional antidepressant medications.

Greenbrook generates revenue by providing in-office TMS courses and SPRAVATO administrations at its clinics and billing third-party payers, with the company handling insurance authorization, claims filing, and reimbursement processing on behalf of patients. Coverage includes major commercial insurers (Aetna, Anthem, Blue Cross Blue Shield, Humana, UnitedHealthcare) as well as Medicare, Medicaid, and Tricare. Its go-to-market is a referral-based enterprise field-sales motion: a nationwide network of Regional Clinical Liaisons and Regional Account Managers builds relationships with referring psychiatrists and physicians, supplemented by industry-conference participation (Psych Congress, APA, Clinical TMS Society, AACAP) and provider-facing webinars. Since inception, Greenbrook reports treating more than 60,000 patients and delivering over 2 million treatments.

The company is privately held with no disclosed parent, external investors, or public listing, and operates with approximately 346 employees. Governance and website control are based in Ontario, Canada, while clinical operations are headquartered in McLean, Virginia. There is no disclosed revenue, no recorded funding rounds, and no M&A activity in the available data.

Name

Greenbrook

Legal name

Greenbrook TMS NeuroHealth Centers

Website

https://greenbrookproviders.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

Greenbrook is a private outpatient mental health provider operating 95 U.S. clinics that deliver FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine for treatment-resistant depression and OCD, serving referred patients via a regional clinical liaison network and major insurance billing.

Ownership category

akta.pro rank

Product category

Mental Health Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)

akta.pro secondary industry

Outpatient Mental Health & Counseling Clinics (HLAFABAC)

Keywords

• Mental health treatment
• TMS therapy
• Esketamine treatment
• Depression treatment
• Outpatient psychiatry

Headquarters

HQ city

Ontario (for corporate/legal purposes)

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

1. Clinical Treatment Services: Greenbrook generates revenue by providing TMS therapy and SPRAVATO nasal spray treatments at their outpatient clinics. Treatments are billed to insurance providers including major insurers like Aetna, Anthem, Blue Cross Blue Shield, Humana, United Healthcare, Medicare, and Medicaid. The company handles insurance authorization, claims filing, and processing on behalf of patients.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Greenbrook operates 95 outpatient mental health treatment clinics across the United States delivering two FDA-cleared/approved therapies — NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy and SPRAVATO (esketamine) Nasal Spray — for adult and adolescent patients with treatment-resistant depression and OCD who have not responded to traditional antidepressant medications. The company accepts referrals from psychiatrists and physicians, manages insurance authorizations and claims on behalf of patients, and returns patients to their referring providers after treatment.

Product overview

Greenbrook operates as a mental health treatment provider offering two primary FDA-approved/cleared therapies: NeuroStar® TMS Therapy (Transcranial Magnetic Stimulation) and SPRAVATO® (esketamine) nasal spray. These treatments target individuals with treatment-resistant depression and OCD who have not found relief through traditional medications. The company provides these services through over 90 outpatient treatment centers nationwide, with patient referral workflows and insurance coordination support. NeuroStar TMS uses non-invasive magnetic stimulation while SPRAVATO provides rapid-acting nasal spray intervention via the glutamate pathway.

Differentiator

Problem solved

Functional benefit

Products and services

• NeuroStar TMS Therapy FDA-cleared non-drug, non-invasive outpatient treatment using focused magnetic pulses (Transcranial Magnetic Stimulation) to reignite dormant synapses for adults and adolescents (ages 15-21) with Major Depressive Disorder and as adjunct treatment for adult OCD who have not achieved satisfactory improvement from prior antidepressant medications. Delivered at Greenbrook's network of 95 outpatient centers nationwide.
• SPRAVATO (esketamine) Nasal Spray FDA-approved nasal spray treatment for adults with treatment-resistant depression, administered at REMS-certified outpatient centers either as monotherapy or with an oral antidepressant. Acts on the glutamate pathway via NMDA receptors and is associated with rapid symptom relief often within weeks.
• Patient Referral and Care Coordination Service End-to-end service for referring psychiatrists and physicians covering patient eligibility evaluation, no-cost consultation scheduling, insurance authorization, claims filing, ongoing clinical updates to the referring provider, and discharge back to the referrer with a treatment outcome summary.
• Insurance Authorization and Reimbursement Management Coverage and reimbursement support for NeuroStar TMS and SPRAVATO treatments, with in-network status across Aetna, Anthem, Blue Cross Blue Shield, Humana, United Healthcare, Medicare, Medicaid, and Tricare, plus assistance determining benefits for patients and providers.

Quantifiable outcome

• 83% of patients responded to NeuroStar acute course treatment; 62% achieved remission (clinician rating)
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Neuronetics, Inc. (NeuroStar)coreTechnology or IntegrationGreenbrook delivers NeuroStar TMS (Transcranial Magnetic Stimulation) therapy, an FDA-cleared treatment for major depressive disorder and OCD. Neuronetics manufactures the NeuroStar Advanced Therapy System. Greenbrook is described as having clinical expertise in delivering this treatment.
• Janssen Pharmaceuticals (SPRAVATO)coreTechnology or IntegrationGreenbrook provides SPRAVATO (esketamine) nasal spray treatment, an FDA-approved medication for treatment-resistant depression. SPRAVATO is manufactured by Janssen Pharmaceuticals and is only available through the restricted SPRAVATO REMS program.
• Insurance Providers (Aetna, Anthem, Blue Cross Blue Shield, Humana, United Healthcare)coreChannel Partner/ Reseller/ DistributorMajor insurance providers cover Greenbrook NeuroStar TMS therapy and SPRAVATO treatment including Aetna, Anthem, Blue Cross Blue Shield, Humana, United Healthcare, Medicare, Medicaid, and Tricare. Greenbrook assists patients with coverage and reimbursement process.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Cerebral: Telehealth-based mental health company offering online evaluation, medication management, and referrals for advanced therapies. Competes for the same treatment-resistant depression patient pool, particularly via digital-first channels.
• Equip Health: Virtual specialty provider focused on eating disorders with family-based treatment. Comparable as an emerging digital-first specialty behavioral health platform that competes for employer-sponsored mental-health spend.
• Talkiatry: Online psychiatry practice staffed by board-certified psychiatrists serving patients across multiple states. Comparable as a competitor for outpatient psychiatric care and as a potential referral source for TMS/esketamine.

Broad incumbents

• Lyra Health: Enterprise mental-health benefits platform providing therapy, coaching, and psychiatric care through employer contracts. Comparable as an alternative channel for TRD care that competes for the same employer-funded patients and referring PCPs.
• MindPath Health: Outpatient behavioral health group offering psychiatry, therapy, and TMS services across multiple states. Comparable as a larger specialty mental-health provider that overlaps with Greenbrook on TMS and TRD treatment.
• Neuronetics: Manufacturer of the NeuroStar Advanced Therapy System and Greenbrook's primary TMS vendor. Adjacent/partner-comparator since Neuronetics also operates training and practice-development programs for TMS providers, including clinics.

Direct peers

• Klaris Clinics: Outpatient ketamine and esketamine (SPRAVATO) provider treating depression and related conditions. Directly comparable on SPRAVATO administration, REMS-monitored outpatient delivery, and psychiatric oversight.
• TMS Centers of America: Specialty outpatient provider of TMS therapy and medication management for depression. Overlaps with Greenbrook on TMS delivery, referral-driven model, and treatment-resistant patient focus.
• Mindful Health Solutions: Multi-state outpatient provider specializing in TMS, esketamine/SPRAVATO, and interventional psychiatry for depression and OCD. Directly comparable in treatment modalities, payor mix, and California/US clinic-based delivery model.
• Pacific TMS & Behavioral Health: TMS-focused clinic network offering NeuroStar TMS and SPRAVATO for treatment-resistant depression in the western US. Comparable in modality mix, physician-supervised delivery, and referral-based patient acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/greenbrook-mental-wellness-centers

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenbrook